about
Adenosine A(2A) Receptor Antagonists and Parkinson's DiseaseDevelopment of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.Sad benefit in face working memory: an emotional bias of melancholic depression.What's in the pipeline for the treatment of Parkinson's disease?Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Dopamine agonists in Parkinson's disease
@ast
Dopamine agonists in Parkinson's disease
@en
Dopamine agonists in Parkinson's disease
@nl
type
label
Dopamine agonists in Parkinson's disease
@ast
Dopamine agonists in Parkinson's disease
@en
Dopamine agonists in Parkinson's disease
@nl
prefLabel
Dopamine agonists in Parkinson's disease
@ast
Dopamine agonists in Parkinson's disease
@en
Dopamine agonists in Parkinson's disease
@nl
P2860
P356
P1476
Dopamine agonists in Parkinson's disease
@en
P2093
Mitsutoshi Yamamoto
P2860
P356
10.1586/14737175.8.4.671
P407
P577
2008-04-01T00:00:00Z